| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3504 | Msk-195 | Potent TRPV1 agonist |
|
| DCC3505 | Mßl-in-2i | Novel potent broad-spectrum metallo-β-lactamase (MβL) inhibitor, inhibiting the MβLs NDM-1, VIM-2, ImiS, and L1 |
|
| DCC3506 | Mt1/2 Agonist (s)-3b | Novel BBB permeable potent MT1 and MT2 ligand (MT1, Ki = 0.031 nM; MT2, Ki = 0.070 nM) with good metabolic stability in human hepatic microsomes |
|
| DCC3507 | Mtc420 | Novel antituberculosis agent. targeting the respiratory chain of Mycobacterium tuberculosis (Mtb) and being effective against multi drug resistant (MDR) Mtb |
|
| DCC3508 | Mtd12813 | Novel minimized theta-defensin, being highly effective against CRE pathogens K. pneumoniae and E. coli in vivo, significantly enhancing survival by promoting rapid host-mediated bacterial clearance and by modulating pathologic cytokine responses, restorin |
|
| DCC3509 | Mtdl-4e | Novel resveratrol-based multitarget-directed ligand, cellularly activating the NRF2-ARE pathway (CD = 9.83 μM), selectively inhibiting both hMAO-B and QR2 (IC 50 s = 8.05 and 0.57 μM), and promoting hippocampal neurogenesis |
|
| DCC3510 | Mthp Hydrobromide | Selective antagonist of melanocortin-4 receptor (MC4R) |
|
| DCC3511 | Mtmox32e | Novel Mithramycin A (MTM) 2'-oxime (MTMox) conjugate, displaying an 11-fold increase in plasma exposure and improved efficacy in an Ewing sarcoma xenograft |
|
| DCC3512 | Mtor Inhibitor-7 | Novel, potent, and selective brain-penetrant ATP-competitive mTOR inhibitor |
|
| DCC3513 | Mtor/hdac1-in-12l | Novel potent dual inhibitor of mTOR and HDAC1 |
|
| DCC3514 | Mtorc1-in-1 | Novel selective inhibitor of mTORC1, yielding potent inhibition of glucose uptake |
|
| DCC3515 | Mtorc1-in-i | Novel selective mTORC1 inhibitor, directly targeting class I glucose transporters |
|
| DCC3516 | Mtor-in-17 | Novel mTOR inhibitor, exhibiting potent anticancer activities against four tumor cell lines, including MCF-7, HeLa, MGC-803, and C6, inducing cell death via apoptosis by targeting both mTORC1 and mTORC2 within cells and arrests the cell cycle of HeLa at t |
|
| DCC3517 | Mtpdds | Novel mitochondria-targeted photoactivatable real-time probe, being phototriggered by either UV (one-photon) or NIR (two-photon) light to form a fluorescent coumarin product and facilitate the release of drug payload |
|
| DCC3518 | Mtsea Hydrobromide | Useful probe in the mapping of membrane proteins, such as ion channels and transports proteins, as well as enzymes and receptors. |
|
| DCC3519 | Mtsea Hydrochloride | Useful probe in the mapping of membrane proteins, such as ion channels and transports proteins, as well as enzymes and receptors. |
|
| DCC3520 | Multitarget Ligand B6 | Novel potent multitarget ligand |
|
| DCC3521 | Mura-in-1 (zinc6129841) | Novel potent MurA inhibitor |
|
| DCC3522 | Murizatoclax | Novel potent and selective MCL-1 inhibitor |
|
| DCC3523 | Mutant Idh1 Inhibitor | Novel potent mutant IDH1 R132H inhibitor |
|
| DCC3524 | Mv061194 | Novel potent and selective cathepsin K (Cat K) inhibitor |
|
| DCC3525 | Mw01-2-151srm | CNS-penetrant, selective restorer of injury- or disease-induced overproduction of proinflammatory cytokines towards homeostasis. Selective suppressor of beta amyloid (Aβ)-induced glia proinflammatory cytokine production |
|
| DCC3526 | mw1219 | Novel GPR119 agonist with Anti-Diabetic Efficacy in db/db Mice |
|
| DCC3527 | Mwp00839 | Novel mitophagy activator |
|
| DCC3528 | mycothiol | Major thiol in most actinomycetes involved in mycothiol biosynthesis and mycothiol-dependent enzymes such as mycothiol-dependent formaldehyde dehydrogenase and mycothione reductase |
|
| DCC3529 | Mycro1 | Novel inhibitor of the protein-protein interactions between the bHLHZip proteins c-Myc and Max |
|
| DCC3530 | Mycro2 | Novel inhibitor of the protein-protein interactions between the bHLHZip proteins c-Myc and Max |
|
| DCC3531 | My-d-4 | Novel inhibitor of zinc finger DHHC domain-containing (zDHHC) enzymes |
|
| DCC3532 | Myotoxin Ii (105-117) | Myotoxin II fragment |
|
| DCC3533 | myovin-1 | Novel potent, reversible and uncompetitive inhibitor of actin-stimulated ATPase activity of myosin V |
|
